Back to CalculatorsBack
Comparison Tool
Oral vs Injectable
Compare oral Orforglipron with injectables
Quick Compare
OrforglipronOral GLP-1
SemaglutideSemaglutide
TirzepatideTirzepatide
| Property | |||
|---|---|---|---|
| Half-Life | ~25-30 hours | ~7 days | ~5 days |
| Mechanism | Oral non-peptide GLP-1 receptor agonist | GLP-1 receptor agonist | Dual GLP-1/GIP receptor agonist |
| Typical Dose | 12-45mg daily | 0.25-2.4mg weekly | 2.5-15mg weekly |
| Frequency | Once daily (oral) | Once weekly | Once weekly |
| Administration | Oral | Subcutaneous | Subcutaneous |
| Onset Time | 2-4 weeks | 2-4 weeks for appetite reduction | 2-4 weeks for appetite reduction |
| Storage | Room temperature | Refrigerated (2-8°C) | Refrigerated (2-8°C) |
| Stability | N/A - oral tablet | 28 days refrigerated | 28 days refrigerated |
| Common Uses | Weight management Type 2 diabetes Convenient oral option | Weight management Type 2 diabetes Appetite control | Weight management Type 2 diabetes Metabolic health |
| Side Effects | Nausea Diarrhea Vomiting | Nausea Vomiting Diarrhea Constipation | Nausea Diarrhea Decreased appetite Vomiting |
Property Comparison
Duration
Quick Onset
Versatility
Tolerability
Use Cases
Stackability
- Orforglipron
- Semaglutide
- Tirzepatide
Scores are derived from peptide properties. Higher = better for that attribute.